SCHEMBL9900995

SCHEMBL9900995

N#Cc1cc(CO)ccc1Oc1ccc(F)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.55
SLC22A12 Q96S37 6/20 0.46
TTR P02766 1/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
PLA2G7 Q13093 1/20 0.39
CNR1 P21554 2/20 0.38
CNR2 P34972 2/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
CYP2C8 P10632 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
SLC22A6 Q4U2R8 1/20 0.38
SLC22A8 Q8TCC7 1/20 0.38
SLC22A11 Q9NSA0 1/20 0.38
HTR2A P28223 1/20 0.38
SLC6A4 P31645 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14656148 0.93 AR (0.56) ARSLC22A12TTRPTGDR2CYP11B1
SCHEMBL14663528 0.92 AR (0.55) ARSLC22A12TTRPTGDR2CYP11B1
SCHEMBL9889478 0.88 AR (0.55) ARSLC22A12CYP4F2CYP4A11HTR2A
SCHEMBL14662731 0.88 AR (0.52) ARSLC22A12TTRCYP11B1CYP11B2
SCHEMBL14656548 0.88 AR (0.52) ARSLC22A12PTGDR2PLA2G7CYP2C8
SCHEMBL14656359 0.88 AR (0.52) ARSLC22A12PTGDR2PLA2G7CYP2C8
SCHEMBL14662704 0.87 AR (0.50) ARTTRPTGDR2CYP11B1CYP11B2
SCHEMBL17302906 0.87 AR (0.51) ARSLC22A12TTRPTGDR2CYP11B1
SCHEMBL14662490 0.86 AR (0.55) ARSLC22A12TTRPTGDR2CYP11B1
SCHEMBL875361 0.86 AR (0.68) ARSLC22A12PLA2G7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300965-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-12 US disclosed
US-11999746-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-06-04 US disclosed
US-20200055863-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-02-20 US disclosed
US-20200055863-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-02-20 US disclosed
US-10428078-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-10-01 US disclosed
US-10428078-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-10-01 US disclosed
EP-3172211-B1 TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 GLAXOSMITHKLINE IP DEV LTD (GB) 2019-07-03 EP disclosed
EP-3172211-B1 TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 GLAXOSMITHKLINE IP DEV LTD (GB) 2019-07-03 EP disclosed
US-20190023715-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-24 US disclosed
US-20190023715-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-24 US disclosed
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-06-26 US disclosed
EP-2736908-A1 BICYCLIC PYRIMIDONE COMPOUNDS Glaxo Group Limited (GB) 2014-06-04 EP disclosed
EP-2649050-A1 COMPOUNDS Glaxo Group Limited (GB) 2013-10-16 EP disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 US disclosed
WO-2013014185-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 WO disclosed
WO-2013014185-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 WO disclosed
WO-2012075917-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055863-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B AR 4494/4885SLC22A12 3059/4885TTR 2416/4885
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS PLA2G7, PLA2G4A, PLA2G1B AR 4584/4885SLC22A12 3061/4885TTR 2451/4885
US-20190023715-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B AR 4494/4885SLC22A12 3059/4885TTR 2416/4885
US-10428078-B2 Compounds PLAAT2, PLA2G12A, PLA2G1B AR 4494/4885SLC22A12 3059/4885TTR 2416/4885
US-20240300965-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B AR 4494/4885SLC22A12 3059/4885TTR 2416/4885
US-20130030012-A1 COMPOUNDS LPCAT1, PLA2G7, PLAAT2 AR 4420/4885SLC22A12 3088/4885TTR 3169/4885
US-11999746-B2 Compounds PLAAT2, PLA2G12A, PLA2G1B AR 4494/4885SLC22A12 3059/4885TTR 2416/4885
US-20130252986-A1 COMPOUNDS LIPG, ENPP2, PLA2G1B AR 4078/4885SLC22A12 1934/4885TTR 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.